CN102058817A - Tibetan medicinal preparation for treating liver diseases - Google Patents
Tibetan medicinal preparation for treating liver diseases Download PDFInfo
- Publication number
- CN102058817A CN102058817A CN2010105265509A CN201010526550A CN102058817A CN 102058817 A CN102058817 A CN 102058817A CN 2010105265509 A CN2010105265509 A CN 2010105265509A CN 201010526550 A CN201010526550 A CN 201010526550A CN 102058817 A CN102058817 A CN 102058817A
- Authority
- CN
- China
- Prior art keywords
- parts
- fructus
- liver
- group
- tibetan medicinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 64
- 208000019423 liver disease Diseases 0.000 title claims abstract description 36
- 210000000582 semen Anatomy 0.000 claims abstract description 21
- 241001247783 Meconopsis Species 0.000 claims abstract description 20
- 238000000338 in vitro Methods 0.000 claims abstract description 16
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims description 54
- 241000628997 Flos Species 0.000 claims description 17
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 16
- 235000001892 vitamin D2 Nutrition 0.000 claims description 16
- 239000011653 vitamin D2 Substances 0.000 claims description 16
- 241001529849 Dracocephalum Species 0.000 claims description 15
- 241000530044 Herpetospermum Species 0.000 claims description 15
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 15
- 230000007159 enucleation Effects 0.000 claims description 15
- 239000009609 fructus phyllanthi Substances 0.000 claims description 15
- 239000002775 capsule Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 21
- 241000196324 Embryophyta Species 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 7
- 235000013399 edible fruits Nutrition 0.000 abstract description 7
- 244000119298 Emblica officinalis Species 0.000 abstract description 4
- 235000015489 Emblica officinalis Nutrition 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 235000011517 Terminalia chebula Nutrition 0.000 abstract description 3
- 244000020518 Carthamus tinctorius Species 0.000 abstract description 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract description 2
- 241000530047 Herpetospermum pedunculosum Species 0.000 abstract description 2
- 244000270834 Myristica fragrans Species 0.000 abstract description 2
- 235000009421 Myristica fragrans Nutrition 0.000 abstract description 2
- 244000294611 Punica granatum Species 0.000 abstract description 2
- 240000000513 Santalum album Species 0.000 abstract description 2
- 235000008632 Santalum album Nutrition 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- JHGWQSGWUPCKNT-UHFFFAOYSA-N 2-tert-butyl-4-methyl-1,3,5-trinitrobenzene Chemical compound CC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C(C(C)(C)C)=C1[N+]([O-])=O JHGWQSGWUPCKNT-UHFFFAOYSA-N 0.000 abstract 1
- 241001127714 Amomum Species 0.000 abstract 1
- 241000271309 Aquilaria crassna Species 0.000 abstract 1
- 206010004542 Bezoar Diseases 0.000 abstract 1
- 229910021532 Calcite Inorganic materials 0.000 abstract 1
- 241000490499 Cardamine Species 0.000 abstract 1
- 244000086363 Pterocarpus indicus Species 0.000 abstract 1
- 235000009984 Pterocarpus indicus Nutrition 0.000 abstract 1
- 235000014360 Punica granatum Nutrition 0.000 abstract 1
- 241000974657 Swertia pseudochinensis Species 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 229940047522 long pepper extract Drugs 0.000 abstract 1
- 239000001702 nutmeg Substances 0.000 abstract 1
- 239000002023 wood Substances 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 50
- 230000006870 function Effects 0.000 description 25
- 210000000952 spleen Anatomy 0.000 description 25
- 241000700159 Rattus Species 0.000 description 21
- 239000000796 flavoring agent Substances 0.000 description 21
- 235000019634 flavors Nutrition 0.000 description 21
- 206010019842 Hepatomegaly Diseases 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 19
- 230000036407 pain Effects 0.000 description 19
- 235000003704 aspartic acid Nutrition 0.000 description 18
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 239000013642 negative control Substances 0.000 description 16
- 230000001737 promoting effect Effects 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 14
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 14
- 229920002674 hyaluronan Polymers 0.000 description 14
- 229960003160 hyaluronic acid Drugs 0.000 description 14
- 230000003908 liver function Effects 0.000 description 14
- 230000002265 prevention Effects 0.000 description 14
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 12
- 206010019799 Hepatitis viral Diseases 0.000 description 12
- 208000002353 alcoholic hepatitis Diseases 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 208000019425 cirrhosis of liver Diseases 0.000 description 11
- 201000001862 viral hepatitis Diseases 0.000 description 11
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 10
- 206010030113 Oedema Diseases 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 102000003929 Transaminases Human genes 0.000 description 8
- 108090000340 Transaminases Proteins 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 231100000240 steatosis hepatitis Toxicity 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102000009027 Albumins Human genes 0.000 description 7
- 108010088751 Albumins Proteins 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 206010019692 hepatic necrosis Diseases 0.000 description 7
- 230000007866 hepatic necrosis Effects 0.000 description 7
- 210000003494 hepatocyte Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000007863 steatosis Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 230000000007 visual effect Effects 0.000 description 6
- 238000010792 warming Methods 0.000 description 6
- 206010000077 Abdominal mass Diseases 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 230000036528 appetite Effects 0.000 description 5
- 235000019789 appetite Nutrition 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 231100000753 hepatic injury Toxicity 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000010254 subcutaneous injection Methods 0.000 description 5
- 239000007929 subcutaneous injection Substances 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108010062580 Concanavalin A Proteins 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010020880 Hypertrophy Diseases 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 239000002932 luster Substances 0.000 description 4
- 230000002175 menstrual effect Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 230000003405 preventing effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 102000006395 Globulins Human genes 0.000 description 3
- 108010044091 Globulins Proteins 0.000 description 3
- 235000019484 Rapeseed oil Nutrition 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- 244000059800 Amomum compactum Species 0.000 description 2
- 235000016426 Amomum compactum Nutrition 0.000 description 2
- 206010006100 Bradykinesia Diseases 0.000 description 2
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 2
- 244000192528 Chrysanthemum parthenium Species 0.000 description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 240000008669 Hedera helix Species 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000403513 Schizostachyum chinense Species 0.000 description 2
- 206010040007 Sense of oppression Diseases 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 241000001522 Terminalia chebula Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002546 agglutinic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000008384 feverfew Nutrition 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 208000020694 gallbladder disease Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000037308 hair color Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 208000018556 stomach disease Diseases 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- DOBIZWYVJFIYOV-UHFFFAOYSA-N 7-hydroxynaphthalene-1,3-disulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=CC(O)=CC=C21 DOBIZWYVJFIYOV-UHFFFAOYSA-N 0.000 description 1
- 241000234599 Aconitum naviculare Species 0.000 description 1
- 241001586435 Aconitum tanguticum Species 0.000 description 1
- 244000296912 Ageratum conyzoides Species 0.000 description 1
- 235000004405 Ageratum conyzoides Nutrition 0.000 description 1
- 241001573260 Amomum krervanh Species 0.000 description 1
- 241001346334 Amomum tsao-ko Species 0.000 description 1
- 241001533085 Aquilaria sinensis Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241001317465 Bambusa textilis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000016535 Capraria biflora Nutrition 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 241000407877 Combretum Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 241000657528 Dalbergia odorifera Species 0.000 description 1
- 241001504825 Dracocephalum tanguticum Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000221079 Euphorbia <genus> Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 241001071804 Gentianaceae Species 0.000 description 1
- DUAGQYUORDTXOR-GPQRQXLASA-N Gentiopicrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)C2=CCOC(=O)C2=CO1 DUAGQYUORDTXOR-GPQRQXLASA-N 0.000 description 1
- DUAGQYUORDTXOR-WULZUDSJSA-N Gentiopicrin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@@H](C=C)C=2C(C(=O)OCC=2)=CO1 DUAGQYUORDTXOR-WULZUDSJSA-N 0.000 description 1
- 206010061998 Hepatic lesion Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 241000983397 Holarrhena pubescens Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 235000019510 Long pepper Nutrition 0.000 description 1
- 241001046986 Meconopsis integrifolia Species 0.000 description 1
- 241001081833 Myristicaceae Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 240000003455 Piper longum Species 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 240000000103 Potentilla erecta Species 0.000 description 1
- 235000016551 Potentilla erecta Nutrition 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 241000221035 Santalaceae Species 0.000 description 1
- 244000272264 Saussurea lappa Species 0.000 description 1
- 235000006784 Saussurea lappa Nutrition 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 241000977603 Swertia chirayita Species 0.000 description 1
- 241000566916 Tomentella Species 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- -1 compound calcium bilirubinate Chemical class 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000010540 rapid respiration Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000011265 semifinished product Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a Tibetan medicinal preparation for treating liver diseases. The Tibetan medicinal preparation for treating the liver diseases consists of the following ingredients in part by weight: 78 to 127 parts of calcite (calcined), 6 to 10 parts of sandalwood, 12 to 20 parts of rosewood heart wood, 8 to 12 parts of Chinese eaglewood, 15 to 25 parts of myrobalan (denucleated), 3 to 5 parts of cardamine, 8 to 12 parts of safflower, 6 to 10 parts of concretio silicea bambusae, 3 to 5 parts of nutmeg, 3 to 5 parts of tsaoko amomum fruit, 12 to 20 parts of emblic leafflower fruit, 9 to 15 parts of seed of pomegranate, 5 to 8 parts of semen holarrhenae, 6 to 10 parts of long pepper extract, 6 to 10 parts of costustoot, 12 to 20 parts of herba dracocephali tangutici, 1.2 to 2 parts of swertia pseudochinensis hara, 8 to 12 parts of Baxiaga, 12 to 20 parts of meconopsis, 6 to 10 parts of herpetospermum pedunculosum, 12 to 20 parts of herba aconiti tangutici, 1.6 to 2.5 parts of in-vitro cultivation bezoar and 0.8 to 1.3 parts of artificial musk. The Tibetan medicinal preparation for treating the liver diseases has obvious curative effects on various diseases. All-natural Tibetan medicinal plants serve as raw materials and no auxiliary materials are added, so the Tibetan medicinal preparation does not have any side effect on a human body, can effectively improve the bioavailability of the human body and can improve human immunity.
Description
Technical field
The present invention relates to a kind of pharmaceutical preparation, particularly a kind of Tibetan medicinal preparation for the treatment of hepatopathy.
Background technology
The sickness rate of all kinds hepatopathy is higher all over the world at present, especially in developing country.Have every year to surpass hepatalgia, the hepatomegaly that the ill virus hepatitis of 500,000 people, alcoholic hepatitis, liver cirrhosis and hepatocarcinoma cause, treating liver disease drug according to estimates at present in the world has 500 kinds more than, but does not still have a kind of can really the radical cure so far.Many hepatopaths develop into nodular cirrhosis owing to can not get effective Drug therapy by hepatalgia and hepatomegaly, and chronic hepatalgia that has and hepatomegaly continue not heal for a long time, and some chronic hepatalgia and hepatomegaly further worsen into hepatocarcinoma.The hepatitis of liver cancer patient and liver cirrhosis all occur in before the hepatocarcinoma, and the importance of hepatalgia and hepatomegaly treatment is described.It can not only make the hepatopath who loses the labour force recover to some extent, and prevention hepatocarcinoma is played active and effective effect, reduces the onset of liver cancer rate.Liver depression and Qi stagnation is one of common syndrome of chronic hepatopathy, how because of feelings will impairing the liver, depression of liver-QI, dredge and to rush down dereliction of duty, but but both perverse and unreasonable manner violate also qi depression to blood stasis of spleen, often show as the hepatic region and do to expand and have a pain, gastral cavity abdomen painful abdominal mass expands, poor appetite, weak, can influence the state of an illness and the patient compliance to treatment.Therefore studying and truly having the liver disease drug of curative effect is the task of top priority.2003.03.19, Patent Office of the People's Republic of China discloses the patent of invention (notification number: CN1403099) of a kind of " a kind of Chinese medicine preparation and preparation method for the treatment of hepatopathy " by name, by percentage by weight is preparation such as injection, solid preparation, cream and the oral liquid of the medically acceptable various dosage forms formed of 0.3-85% Radix Gentianae active component extract and 15-99.7% pharmaceutic adjuvant, wherein main active gentiopicroside content 〉=90% in the Radix Gentianae active component extract.This invention is based on Radix Gentianae, and the prevention and the quality that are primarily aimed at hepatocarcinoma have certain effect.2003.01.01 Patent Office of the People's Republic of China discloses the patent of invention of a kind of by name " medicine of treatment hepatopathy ", and (notification number: CN1387908), the weight ratio of its raw material is: Radix Puerariae 25-45, Herba Menthae 20-50, Semen Lablab Album 20-35, Fructus Alpiniae Oxyphyllae 5-25, Pericarpium Citri Reticulatae 10-35, Fructus Amomi 5-30.Fructus Amomi, Semen Lablab Album, Fructus Alpiniae Oxyphyllae, Pericarpium Citri Reticulatae, Radix Puerariae are processed into fine powder, Herba Menthae are soaked produced supernatant, fine powder, supernatant are mixed, add the ethanol lixiviate, make the extractum semi-finished product and make capsule or tablet or electuary or water preparation again.This patent is to alcoholic liver injury, fatty liver, and liver cirrhosis and hepatitis have remarkable efficacy.Still lack to improve human bioavailability at present, at the prevention of the hepatopathy of acute and chronic hepatalgia and hepatomegaly and the medicine of treatment.
Summary of the invention
The present invention provides a kind of Tibetan medicinal preparation for the treatment of hepatopathy for solving the above-mentioned deficiency of prior art.The present invention's treatment is evident in efficacy by hepatalgia, hepatomegaly that viral hepatitis, alcoholic hepatitis, liver cirrhosis, hepatocarcinoma cause.Simultaneously, the present invention is a raw material with pure natural Tibetan medicine plant, does not add any adjuvant, without any side effect, and can effectively improve human bioavailability to human body, improves body immunity.
Technical solution of the present invention is made of following content:
A kind of Tibetan medicinal preparation for the treatment of hepatopathy is characterized in that: described preparation is made of the component of following parts by weight: Mirabilitum crystallina (calcine) 78～127; Lignum Santali Albi 6～10; Lignum Dalbergiae Odoriferae 12～20; Lignum Aquilariae Resinatum 8～12; Fructus Chebulae's (enucleation) 15～25; Fructus Amomi Rotundus 3～5; Flos Carthami 8～12; Concretio Silicea Bambusae 6～10; Semen Myristicae 3～5; Fructus Tsaoko 3～5; Fructus Phyllanthi 12～20; Semen Granati 9～15; seed of Cortex Holarrhenae Antidysentericae 5～8; Fructus Piperis Longi 6～10; the Radix Aucklandiae 6～10; tangut dragonhead 12～20; Herba Swertiae bimaculatae 1.2～2g; BAXIAGA 8～12; Herba meconopsis integrifoliae 12～20; Herpetospermum caudigerum Wall. 6～10; list loud, high-pitched sound 12～20; In vitro cultured Calculus Bovis 1.6～2.5; the artificial Moschus 0.8～1.3.
Preferably, described preparation is made of the component of following parts by weight: Mirabilitum crystallina (calcine) 100～110; Lignum Santali Albi 8～9; Lignum Dalbergiae Odoriferae 16～18; Lignum Aquilariae Resinatum 10～12; Fructus Chebulae's (enucleation) 20～22; Fructus Amomi Rotundus 4～5; Flos Carthami 10～12; Concretio Silicea Bambusae 8～9; Semen Myristicae 4～5; Fructus Tsaoko 4～5; Fructus Phyllanthi 16～18; Semen Granati 12～14; seed of Cortex Holarrhenae Antidysentericae 6～8; Fructus Piperis Longi 8～9; the Radix Aucklandiae 8～9; tangut dragonhead 16～18; Herba Swertiae bimaculatae 1.6～1.8; BAXIAGA 10～12; Herba meconopsis integrifoliae 16～18; Herpetospermum caudigerum Wall. 8～9; list loud, high-pitched sound 16～18; In vitro cultured Calculus Bovis 2～2.3; the artificial Moschus 1～1.1.
Optimum, described preparation is made of the component of following parts by weight: Mirabilitum crystallina (calcine) 106, Lignum Santali Albi 8.5, Lignum Dalbergiae Odoriferae 17, Lignum Aquilariae Resinatum 10.6, Fructus Chebulae's (enucleation) 21.2, Fructus Amomi Rotundus 4.2, Flos Carthami 10.6, Concretio Silicea Bambusae 8.5, Semen Myristicae 4.2, Fructus Tsaoko 4.2, Fructus Phyllanthi 17, Semen Granati 12.7, seed of Cortex Holarrhenae Antidysentericae 6.4, Fructus Piperis Longi 8.5, the Radix Aucklandiae 8.5, tangut dragonhead 17, Herba Swertiae bimaculatae 1.7, BAXIAGA 10.6, Herba meconopsis integrifoliae 17, Herpetospermum caudigerum Wall. 8.5, list loud, high-pitched sound 17, In vitro cultured Calculus Bovis 2.1, artificial Moschus 1.1.
Described preparation is a capsule preparations, also can be tablet or granule, dispersant.
Mirabilitum crystallina another name Mirabilitum crystallina of the present invention, water stone, magpie stone, latin name Calcitum, GypsumRubrum.Mineral crystal for the Sulfates mineral.The property suffering, one-tenth, cold.GUIXIN, stomach, kidney channel.The function clearing away heat-fire, sharp key, detumescence.
Lignum Santali Albi is the heartwood of Santalaceae plant Lignum Santali Albi Santalum album L. trunk.Nature and flavor suffering, temperature.Return spleen, stomach, the heart, lung meridian.Function circulation of qi promoting warming middle-JIAO, the appetizing pain relieving.
Lignum Dalbergiae Odoriferae is the dry duramen of leguminous plant Lignum Dalbergiae Odoriferae Dalbergia odorifera T.Chen trunk and root.Nature and flavor suffering, hardship, tepor.Return liver, spleen channel.The function promoting flow of QI and blood, pain relieving, hemostasis.
Lignum Aquilariae Resinatum is the timber that thymelaeceae plant Lignum Aquilariae Resinatum Aquilaria sinensis (Lour.) Gilg contains resin, nature and flavor suffering, hardship, tepor.Return spleen, stomach, kidney channel.The function promoting the circulation of QI to relieve pain, warming middle-JIAO to arrest vomiting, helping inspiration to relieve asthma.Be used for the vexed pain of breast abdominal distention, gastrofrigid vomiting singultus, the QI rising in reverse order of suffering from a deficiency of the kidney dyspnea with rapid respiration.
Fructus Chebulae's (enucleation) is the dry mature fruit of Combretum Racemosum plant Fructus Chebulae Terminalia chebula Retz. or fine hair Fructus Chebulae Terminalia chebula Retz.var.tomentella Kurt..Nature and flavor hardship, acid, puckery, flat.Return lung, large intestine channel.The function astringing intestine to stop diarrhea is astringed the lung, the pathogenic fire reducing sore-throat relieving.
Fructus Amomi Rotundus is the dry mature fruit of zingiberaceous plant Fructus Amomi Rotundus Amomum kravanh Pierre ex Gagnep. or amomum compactum Soland ex Maton Amomum compactum Soland ex Maton.Nature and flavor suffering, temperature.Return lung, spleen, stomach warp.The function removing dampness painful abdominal mass that disappears, circulation of qi promoting warming middle-JIAO, appetite-stimulating indigestion-relieving.Be used for turbid damp obstructing in middle-JIAO, anorexia, hygropyrexia from the beginning of, uncomfortable in chest not hungry, the cold-damp vomiting, chest and abdomen swelling and pain, food stagnation does not disappear.
Flos Carthami is the dried floral of feverfew Flos Carthami Carthamus tinctorius L..Nature and flavor suffering, temperature.GUIXIN, Liver Channel.The function promoting blood circulation to restore menstrual flow, eliminating stasis to stop pain.
Concretio Silicea Bambusae is the dried block of juice in the bars such as grass Chinese textile bamboo Bambusa textilis MeClure or schizostachyum chinense Rendle Schizostachyum chinese Rendle.Nature and flavor are sweet, cold.GUIXIN, Liver Channel.The function clear heat and eliminate phlegm, cool heart arresting convulsion.
Semen Myristicae is the dry kernel of myristicaceae plant Semen Myristicae Myristica fragrans Houtt..Nature and flavor suffering, temperature.Return spleen, stomach, large intestine channel.The function warming middle-JIAO to promote flow of QI, relieving diarrhea with astringents.Be used for Deficiency and coldness of spleen and stomach, incessant chronic diarrhea, abdominal distention, lack of appetite vomiting.
Fructus Tsaoko is the dry mature fruit of zingiberaceous plant Fructus Tsaoko Amomum tsao-ko Crevost et Lemaire.Nature and flavor suffering, temperature.Return spleen, stomach warp.Function dampness warming middle-JIAO, the expectorant preventing the attack (or recurrence) of malaria.
Emblic subsystem Tibetan conventional crude drugs.Dry mature fruit for euphorbia plant Fructus Phyllanthi Phyllanthus emblica L..Nature and flavor are sweet, sour, puckery, cool.Attach to the lung and stomach meridians.The function clearing away heat and cooling blood, promoting digestion and invigorating the stomach, the cough-relieving of promoting the production of body fluid.Be used for the heat in blood blood stasis, dyspepsia, abdominal distention, cough, laryngalgia, xerostomia.Fructus Piperis Longi is dry near maturation or the mature fruit cluster of Piperaceae plant Fructus Piperis Longi Piper longum L..Nature and flavor suffering, heat.Return stomach, large intestine channel.The function warming spleen and stomach for dispelling cold, therapeutic method to keep the adverse QI flowing downwards pain relieving.
The Radix Aucklandiae is the dry root of feverfew Radix Aucklandiae Aucklandia lappa Decne..Nature and flavor suffering, hardship, temperature.Return spleen, stomach, large intestine, three warmers, gallbladder meridian.The function promoting the circulation of QI to relieve pain, strengthening the spleen to promote digestion.Be used for breast gastral cavity distending pain, heavy behind the dysentery, food stagnation does not disappear, anorexia.
In vitro cultured Calculus Bovis is made mother solution with the fresh bile of bovid cattle Bos taurus domesticus Gmelin, adds deoxycholic acid, cholic acid, compound calcium bilirubinate etc. and makes.Function clears away heart-fire, and eliminating phlegm is had one's ideas straightened out, cool liver, and endogenous wind stopping is understood.
Artificial Moschus's nature and flavor suffering, temperature.GUIXIN, spleen channel.The function refreshment of having one's ideas straightened out, promoting blood circulation to restore menstrual flow, reducing swelling and alleviating pain.
Herpetospermum caudigerum Wall. is the dry seed of cucurbitaceous plant Fructus Herpetospermi pedunculosi Herpetospermum pedunculosum (Sex.) Baill..Nature and flavor are cold, hardship.The function removing fire from the liver, gallbladder-heat, detoxifcation.It is sick to be used for the treatment of red crust, hepatopathy, gallbladder disease and dyspepsia.
Seed of Cortex Holarrhenae Antidysentericae is the dry seed of apocynaceae plant tellicherry bark Holarrhena antidysenterica Wall.exA.DC..Nature and flavor hardship, puckery, cold.The function heat clearing away, function of gallbladder promoting, antidiarrheal.It is sick to be used for red crust, liver-gallbladder disease, gastrointestinal calentura, diarrhoea, dysentery.
Tangut dragonhead is the dry aerial parts of labiate tangut dragonhead Dracocephalum tanguticum Maxim..Nature and flavor are sweet, bitter, and are cold.The function removing heat from the liver, hemostasis, the skin ulcer that heals, yellow fluid reducing.Be used for liver, gastric heat, yellow fluid class disease, mass formed by blood stasis, the open sore part does not heal.Seedling is used for ascites, edema.
Semen Granati is the dry seed of Punicaceae plant pomegranate Punica granatum L..Nature and flavor acid, sweet, temperature, profit.Function cures mainly Baconic's sympotoms caused by cold factors, cold syndrome of the stomach disease and all gastropathy.
Herba meconopsis integrifoliae is the dry herb of the full edge Herba meconopsis integrifoliae of bloodroot Meconopsis integrifolia (Maxim.) Franch. and Flos meconopsis quintuplinerviae Meconapsi s quintupl inervia Regel, Herba meconopsis integrifoliae Meconopsi slancifolia (Fra-nch.) Franch. that comes into leaves etc.Nature and flavor are sweet, puckery, cold.The function heat clearing away, diuresis, antiinflammatory, pain relieving.
Herba Swertiae bimaculatae is the dry herb of gentianaceae plant Indian Herba Swertiae bimaculatae Swertia chirayita (Roxb.exFlemi) Karsten.The nature and flavor hardship, cool, rough.Function liver heat removing function of gallbladder promoting moves back all heat.
The list loud, high-pitched sound is the dry herb of ranunculaceae plant Herba Aconiti bonga Aconitum naviculare stapf. or Aconitumtanguticum (Maxim.) Stapf.Nature and flavor hardship, cold.The function heat-clearing and toxic substances removing.
BAXIAGA is goatweed Herba Veronicae Veronica eriogine H.WinKl. wait the dry herb that belongs to kindred plant together.Nature and flavor hardship, cold.Function heat clearing away, more skin ulcer, granulation promoting, hemostasis.
Effect below by existing related preparations of clinical experiment contrast contrast and preparation of the present invention.
1 materials and methods
1.1 case is collected 45 routine patients all from the court's outpatient service, all meets the chronic viral hepatitis B differentiation of symptoms and signs for classification of syndrome standard of hepatopathy Professional Committee of Chinese Chinese medicine association revision in 1991, belongs to Liver depression and Qi stagnation.Primary symptom comprises that hepatic region feeling of distension and oppression, hepatalgia, mood are gloomy, and inferior disease has that gastral cavity abdomen painful abdominal mass expands, poor appetite, weak, dizzy, and it is promptly diagnosable to have in the primary symptom one and time two persons of disease.Wherein male 32 examples, women 13 examples; 36.6 years old mean age, maximum 55 years old, minimum 21 years old; The state of an illness belongs to slight person's 33 examples, moderate 12 examples.Two groups have comparability.
Organize 30 examples 1.2 set up two groups of treatments separately, matched group 15 examples.
1.3 Therapeutic Method treatment group is given capsule preparations of the present invention, 1 time 4,2 times on the 1st, oral: matched group gives existing preparation secret formula pulvis refrigerans, 1 1g is 2 times on the 1st, oral.Two groups is 1 course of treatment with 2 weeks all, and timely record when the state of an illness changes was made curative effect when finishing and judge in 2 weeks.
1.4 observation item and index symptom, liver function.Symptom by do not have, light, in, scored 0,1,2,3 fens heavily respectively.
1.5 efficacy assessment standard produce effects: conscious fundamental symptoms disappears, or integration descends more than 80% after the treatment, and liver function is normal again;
Effectively: feel that fundamental symptoms alleviates, or treatment back integration descends more than 50% the liver function improvement; Invalid: conscious no significant change, liver function is not improved; Worsen: subjective symptoms increases the weight of, and liver function is further unusual.
2 results
2.1 two groups of each symptoms all have more significantly and improve behind the symptom treatment, wherein with hepatic region feeling of distension and oppression, hepatalgia, gastral cavity abdomen painful abdominal mass expand improve more obvious.See table 1 for details.
Table 1 doing well,improving situation
Syndrome integration comparison before and after the table 2 liang group treatment (X ,-s)
2.2 the two groups of liver functions in liver function treatment back have certain improvement, but there was no significant difference (P＞0.05) before and after the treatment.See table 3 for details.
Table 3 liang group changes of liver function situation (X-,-S)
2.3 the two groups of curative effects in curative effect treatment back are all comparatively satisfied, treatment group produce effects 4 examples, and effective 18 examples, invalid 6 examples worsen 2 examples, total effective rate 73.33% matched group produce effects 2 examples, effective 7 examples, invalid 5 examples worsen 1 example, total effective rate 60%.Compare there was no significant difference (P＞0.05) between two groups.
3 conclusions
Liver depression and Qi stagnation is one of common syndrome of chronic hepatopathy, how because of feelings will impairing the liver, depression of liver-QI, dredge and to rush down dereliction of duty, but but both perverse and unreasonable manner violate also qi depression to blood stasis of spleen, often show as the hepatic region and do to expand and have a pain, gastral cavity abdomen painful abdominal mass expands, poor appetite, weak, can influence the state of an illness and the patient compliance to treatment.The present invention is made up of Mirabilitum crystallina (calcine), Lignum Santali Albi, Lignum Dalbergiae Odoriferae, Lignum Aquilariae Resinatum, Fructus Chebulae's (enucleation), Fructus Amomi Rotundus, Flos Carthami, Concretio Silicea Bambusae, Semen Myristicae, Fructus Tsaoko, Fructus Phyllanthi, Semen Granati, seed of Cortex Holarrhenae Antidysentericae, Fructus Piperis Longi, the Radix Aucklandiae, tangut dragonhead, Herba Swertiae bimaculatae, BAXIAGA, Herba meconopsis integrifoliae, Herpetospermum caudigerum Wall., list loud, high-pitched sound, In vitro cultured Calculus Bovis, artificial Moschus etc.Lignum Santali Albi, Lignum Dalbergiae Odoriferae, Lignum Aquilariae Resinatum, Fructus Amomi Rotundus, Semen Myristicae, Fructus Tsaoko, the Radix Aucklandiae, Fructus Piperis Longi promoting the circulation of QI to relieve pain; Artificial Moschus, Flos Carthami promoting blood circulation to restore menstrual flow, pain relieving; Fructus Phyllanthi, Concretio Silicea Bambusae, Fructus Chebulae's (enucleation), Herba Swertiae bimaculatae, tangut dragonhead, BAXIAGA, Herba meconopsis integrifoliae, Herpetospermum caudigerum Wall., list loud, high-pitched sound, In vitro cultured Calculus Bovis, seed of Cortex Holarrhenae Antidysentericae heat-clearing and toxic substances removing, removing heat from blood heat; Mirabilitum crystallina (calcine) is releived liver suddenly; Semen Granati cures mainly Baconic's sympotoms caused by cold factors; Full side share, heat-clearing and toxic substances removing, and removing heat from blood heat is changed Baconic's phlegm-damp, pain relieving.It is comparatively satisfied that the present invention treats hepatalgia, hepatomegaly, xanthochromia curative effect that viral hepatitis, alcoholic hepatitis, liver cirrhosis, hepatocarcinoma cause, and aspect taking, patient's compliance is better, as the adjuvant drug of chronic hepatopathy, is worth clinical application.
Lignum Santali Albi, Lignum Dalbergiae Odoriferae, Lignum Aquilariae Resinatum, Fructus Amomi Rotundus, Semen Myristicae, Fructus Tsaoko, the Radix Aucklandiae, Fructus Piperis Longi promoting the circulation of QI to relieve pain among the present invention; Artificial Moschus, Flos Carthami promoting blood circulation to restore menstrual flow, pain relieving; Mirabilitum crystallina (calcine), Fructus Phyllanthi, Concretio Silicea Bambusae, Fructus Chebulae's (enucleation), Herba Swertiae bimaculatae, tangut dragonhead, BAXIAGA, Herba meconopsis integrifoliae, Herpetospermum caudigerum Wall., list loud, high-pitched sound, In vitro cultured Calculus Bovis, seed of Cortex Holarrhenae Antidysentericae heat-clearing and toxic substances removing, removing heat from blood heat; Semen Granati cures mainly Baconic's sympotoms caused by cold factors; Full side share, heat-clearing and toxic substances removing, and removing heat from blood heat is changed Baconic's phlegm-damp, pain relieving.The present invention is a raw material with pure natural Tibetan medicine plant, does not add any adjuvant, without any side effect, and can effectively improve human bioavailability to human body, improves body immunity.
For showing the therapeutic effect of pharmaceutical preparation of the present invention, the present invention is done a series of analyses and the contrast experiment is as follows respectively to hepatopathy:
The hepatalgia that viral hepatitis, alcoholic hepatitis and liver cirrhosis, hepatocarcinoma are caused and the checking of hepatomegaly therapeutical effect:
Hepatalgia and hepatomegaly prevention and therapeutical effect to viral hepatitis, alcoholic hepatitis and liver cirrhosis, hepatocarcinoma cause can be confirmed in following many-side respectively by zoopery, and particular content and process are as follows:
Laboratory animal: cleaning level wistar male rat, 210 ± 10g (Sichuan Academy of Medical Sciences's medical experiment animal center provides).
Medicine and reagent: 40% carbon tetrachloride rapeseed oil solution (4 ℃ of preservations are standby), the analytical pure carbon tetrachloride is produced by Tianjin Chemical Reagents Factory No.1, and rapeseed oil is the edible product oil of commercially available hard-cover human body; 0.9% medical saline is that Kelun Pharm Ind Co., Ltd., Sichuan produces lot number H 51021157; Preparation of the present invention is prepared by preparation research central laboratory; Albumin, globulin, the amino transaminase of alanine, the amino transaminase determination test kit of aspartic acid are provided by Beijing Zhongsheng Beikong Biological Science ﹠ Technology Co., Ltd.; Hyaluronic acid is measured test kit and is provided by Senxiong Science ﹠ Technology Industry Co., Ltd., Shanghai, and all the other reagent are analytical pure, and water is redistilled water.
Experimental technique: rat is divided into matched group (11) after adapting to 5 days at random, model group (75), heavy dose of group (15), small dose group (15); All the other each groups press 5ml/kg subcutaneous injection 40% carbon tetrachloride rapeseed oil solution to the last fortnight except that matched group per 2 days morning, and later per 2 days injected dose in the morning changes 3ml/kg into, and matched group is to wait dosage medical saline replacement carbon tetrachloride solution; Each group injection afternoon on the same day, matched group and model group are pressed 0.33ml/kg subcutaneous injection normal saline, large and small dosage group respectively by 0.25,0.125g/kg feeds; Except that control group fed tap water and common standard feedstuff, all the other each groups are drunk 10% ethanol water (volume ratio), and the last fortnight low albumen feedstuff (cholesterol of 79.5% Semen Maydis flour+20% Adeps Sus domestica+0.5%) of high fat of feeding changes later on and feeds low albumen feedstuff (99.5% Semen Maydis flour+0.5% cholesterol); In the prevention stage,, then stop to annotate carbon tetrachloride solution once if rat body weight descends 10% than last
[5]Extracting 14 at random out from model group behind two first quarter moons changes and feeds the common standard feedstuff and tap water enters outside the treatment stage, all the other rats all stop eating do not cut off the water 18 hours after etherization, extract eyeball and get blood, the centrifugal 10min of 4000r/min behind the room temperature 30min gets each index of determination of serum; Observe liver color and luster, form, liver, spleen are weighed and are made liver section, and the prevention stage finishes.14 rats that model group is extracted out are divided into two groups more at random and enter treatment stage, every group 7, treatment matched group and treatment are organized per 2 days by feeding by 0.66ml/kg subcutaneous injection normal saline and 0.25g/kg respectively, and the common standard of all feeding feedstuff and tap water were respectively organized rat with the method processing after 18 days.
Verification method:
Blood parameters is measured: albumin, globulin, the amino transaminase of aspartic acid, the amino transaminase of alanine, hyaluronic acid enzymatic determination adopt test kit.
Hepatic pathology: get liver Da Ye, 12% formalin fixed, paraffin embedding, conventional section, H E dyeing, the variation of liver tissues of rats pathology is respectively organized in observation under the light microscopic.
Data analysis: adopt STATISTICAL 6.0 deal with data, the result is with mean+SD
Expression, relatively with the t check, P＜0.05 is a significant difference between group, P＜0.01 is a utmost point significant difference.
The checking result:
One, the preparation of the present invention hepatalgia that viral hepatitis, alcoholic hepatitis and liver cirrhosis, hepatocarcinoma are caused and the preventive effect of hepatomegaly.
The modeling situation: the prevention stage is compared with matched group when finishing, and model group rat hair color is gloomy, stiff and the movable obvious minimizing of taking action, bradykinesia, appetite, amount of drinking water all obviously reduce, rats'liver, spleen enlargement (table 3), liver color and luster dimness, surface visible obviously tuberosity and white granular kick, the edge is uneven, and its section is mostly visible pseudolobuli under light microscopic, sinus hepaticus narrows down even disappears, liver rope arrangement disorder.ALT, AST, HA significantly raise (P＜0.01) than matched group, and A, G significantly reduce (P＜0.01) (table 1), liver cirrhosis modeling success.
Table 1 preparation of the present invention to the influence of rat liver function biochemical indicator (
N=7)
Annotate:
aP＜0.05,
bP＜0.01 is compared with model group;
cP＜0.05 is compared with small dose group.
1. blood parameters: with the matched group ratio, model group A, G significantly reduce (P＜0.01), and ALT, AST, HA significantly raise (P＜0.01), and A/G is inverted.Compare with model group, heavy dose of injection group significantly raise A (P＜0.01) and G (P＜0.05) significantly reduce ALT, AST (P＜0.01) and HA (P＜0.05).Small dose group significantly reduces outside the AST (P＜0.05), and all the other liver function indexes are compared not statistically significant with model group.Large and small dosage group is compared, and heavy dose of group remarkable rising A (P＜0.05), significantly reduces AST (P＜0.05) and ALT (P＜0.05) (table 1).Illustrate that said preparation has certain protecting the liver and anti-hepatomegaly effect to liver cirrhosis, heavy dose of effect is better than low dose.
2. hepatic pathology: liver reads sheet and standards of grading are carried out by West China HSPH of Sichuan University Pathological Staff Room, except that 0,1,2,3,4 fen five grade are counted in fibroplasia, all the other indexs are all counted 0,1,2,3 fen four grade, and statistics is respectively organized the rat quantity under the different score values.The obviously visible down pseudolobuli of model group liver section light microscopic is compared with model group, and heavy dose of group steatosis, fibroplasia, hepatic necrosis, sinus hepaticus vascularization degree obviously alleviate, and pseudolobuli appears in none example.Heavy dose of group is except that the hepatocyte edema, and all the other each indexs all significantly are lighter than model group.Small dose group only hepatic necrosis obviously is lighter than model group.Compare between two dosage groups, heavy dose of group steatosis, endochylema solidify, fibroplasia, cell infiltration degree obviously are lighter than small dose group (table 2).
Table 2 rat liver section scoring situation (n=7)
Annotate: hepatocyte edema number in three different visuals field of same section par less than 10% 1 minutes, 10-15% meter 2 minutes, 15-20% counted 3 fens; Can get the steatosis cell quantity on average less than 25% 1 minutes with method, 25-50% meter 2 minutes, 50-75% meter 3 minutes; Endochylema solidifies cell quantity on average less than 5% 1 minutes, 5-10% meter 2 minutes, 10-20% meter 3 minutes; The hepatic necrosis cell quantity is on average less than 5% 1 minutes, 5-10% meter 2 minutes, 10-20% meter 3 minutes; Fibroplasia is visible hypertrophy meter 1 minute, and obviously visible hypertrophy meter 2 minutes does not form the meter 3 minutes of whole pseudolobulis in the visual field, and whole visual field all forms the meter 4 minutes of pseudolobuli.
3. liver, spleen index and mortality rate: compare model group rats'liver, the obvious enlargement of spleen, liver, spleen index significantly higher (P＜0.01) with matched group.Compare heavy dose of group liver index (P＜0.05) significantly on the low side with model group.Two dosage groups are compared, and the liver index of heavy dose of group significantly is lower than small dose group (P＜0.05).Though its excess-three group liver, spleen all have enlargement in various degree except that matched group, but heavy dose of group liver enlargement degree obviously is lighter than model group and small dose group (P＜0.05), spleen index is not statistically significant between the three, the prompting splenomegaly is not influenced by Chinese medicine may, mortality rate comparing difference big (table 3) in twos between four groups.
Table 3 respectively organize rats'liver, spleen index and mortality rate (
N=7)
Annotate:
aP＜0.05,
bP＜0.01 is compared with model group;
cP＜0.05 is compared with small dose group.
Two, the preparation of the present invention hepatalgia that viral hepatitis, alcoholic hepatitis and liver cirrhosis, hepatocarcinoma are caused and the therapeutical effect of hepatomegaly.
1. blood parameters: detected two groups of rat liver function indexes the 5th, 11,18 day of treatment respectively.Comparison sheet 1 and table 4 as can be seen, remove the cause of disease after, matched group and treatment group rat A and G raise than before to some extent, AST, ALT and HA significantly reduce than before, illustrates that rat exists certain spontaneous recovery to be inclined to after removing the cause of disease.Compare with the contemporaneity matched group, the treatment group significantly reduces (P＜0.05), HA significantly raise (P＜0.05) at the 11st day G, AST, the treatment group significantly reduces AST (P＜0.01) and ALT (P＜0.05) in the time of the 18th day, illustrate that preparation of the present invention has certain treatment liver cirrhosis effect, but treatment group A, G and HA continue to raise or reduce in therapeutic process, may be too short owing to treatment time, due to therapeutic effect fails fully to stablize (table 4).
Table 4 preparation of the present invention to the influence of liver function biochemical indicator (
N=7)
Annotate: * P＜0.05, * * P＜0.01 is compared with the contemporaneity matched group.
2. hepatic pathology: liver reads sheet and standards of grading are still carried out by West China HSPH of Sichuan University Pathological Staff Room, and standards of grading are identical with prevention stage 2.3.2 hepatic pathology.Compare with matched group, the apparent color and luster of treatment group rat liver is better than matched group mostly, and surperficial white granule is less, and light microscopic is observed down and found, treatment group hepatocyte edema, endochylema solidify, fibroplasia and cell infiltration degree totally are lighter than matched group, but both still visible pseudolobulis (table 5).
Table 5 rat liver section scoring situation (n=7)
3. liver, spleen index and mortality rate: when treatment stage finished, two groups of rats did not all have death; Matched group liver, spleen index are respectively 4.16 ± 0.34,3.94 ± 0.48; Treatment group liver, spleen index are respectively 3.98 ± 0.54,3.16 ± 0.21; Though treatment group liver, spleen index be all less than matched group, not statistically significant.
Above result of study shows: hepatalgia and hepatomegaly prevention and therapeutical effect that preparation of the present invention causes viral hepatitis, alcoholic hepatitis and liver cirrhosis, hepatocarcinoma.
Hepatalgia and hepatomegaly prevention and therapeutical effect to viral hepatitis, alcoholic hepatitis and liver cirrhosis, hepatocarcinoma cause can be confirmed in following many-side respectively by zoopery, and particular content and process are as follows:
Laboratory animal: 48 of SPF level Balb/c male mices, in 8 ages in week, body weight 20 ± 2g purchases the medical experiment animal center in Sichuan Academy of Medical Sciences.Experiment is divided into prevention and treats two stages.In the prevention stage, healthy mice is divided into 4 groups at random: 24 of model group, each 8 of negative control group, heavy dose of group, small dose group.Treatment stage will prevent the remaining Liver Fibrosis Model mice in stage model group sampling back to be divided into negative control group and medication therapy groups at random, every group each 8.
Medicine and reagent: Con A specification is that 25mg/ props up, available from Sigma company.Be dissolved in the solution that medical saline is made into 2.5mg/ml during experiment.Albumin (Alb), total protein (TP) are measured test kit and are provided by Beijing Zhongsheng Beikong Biological Science ﹠ Technology Co., Ltd.; The amino transaminase (ALT) of alanine, the amino transaminase of aspartic acid (AST) builds up bio-engineering research by Nanjing is provided; Hyaluronic acid (HA) is measured test kit, is provided by Senxiong Science ﹠ Technology Industry Co., Ltd., Shanghai; And preparation of the present invention.
Experimental technique: in the prevention stage, the negative control group mice is pressed the dosage tail vein injection saline of 12.5mg/kg, and all the other each groups wait dosage tail vein injection Con A solution.1 time weekly, continued for 9 weeks.Simultaneously, preparation of the present invention is fed administration by big (0.25g/kg), little (0.125g/kg) dosage group.Negative control group and model group are then pressed the dosage subcutaneous injection normal saline of 6.6ml/kg, per 3 days 1 time, continue for 9 weeks.6 model group mices of 9 weeks back sampling, extract eyeball and get blood, with the centrifugal 10min of 4000r/min, get each index of determination of serum behind the room temperature placement 30min, observe the liver appearance, cut the hepatomegaly leaf, 10% formalin fixed, paraffin embedding, conventional section, HE dyeing, light microscopic are observed liver histopathology down and are changed.After confirming the modeling success, horse back is in kind handled negative control, large and small dosage is respectively organized mice.
Treatment stage, negative control group mice are pressed the dosage subcutaneous injection normal saline of 6.6ml/kg, and the medication therapy groups mice is fed preparation of the present invention by the dosage of 0.25g/kg, continue 31 days.6 mices of every group of sampling are cooked capillary tube puncture eye socket venous plexus and get blood weekly during this period, and preparation serum is measured every index, dynamic observes the treatment situation of mice.
Verification method:
Blood parameters is measured: albumin, globulin, the amino transaminase of aspartic acid, the amino transaminase of alanine, hyaluronic acid enzymatic determination adopt test kit.
Hepatic pathology: get liver Da Ye, 12% formalin fixed, paraffin embedding, conventional section, H E dyeing, the variation of liver tissues of rats pathology is respectively organized in observation under the light microscopic.
Data analysis: adopt STATISTICAL 6.0 deal with data, the result is with mean+SD
Expression, relatively with the t check, P＜0.05 is a significant difference between group, P＜0.01 is a utmost point significant difference.
The checking result:
One, preparation of the present invention is to the hepatalgia that viral hepatitis, alcoholic hepatitis and liver cirrhosis, hepatocarcinoma are caused and the prevention and the therapeutical effect of hepatomegaly.
The modeling situation: the prevention stage proceeded to after 4 weeks, and model group is compared the obvious inappetence that occurred with feminine gender to group, and chaeta is in disorder, and hair color is gloomy, phenomenons such as bradykinesia.The prevention stage finishes the perusal of back taking-up liver and also can find model group mouse liver color and luster dimness, and the edge is uneven.Serum testing result (table 1) display model group ALT, AST, HA is than negative control group all extremely significantly higher (P＜0.01), and G, A/G extremely significantly reduce (P＜0.01).The structure of this explanation Liver Fibrosis Model is successful.But this model group of albumin was compared the significant difference that expection do not occur during serum detected with negative control group, and estimation is because the albuminous half-life reaches 19 days
[11]Though the model group mice has reduced albuminous synthetic after hepatic injury, synthetic albumin does not divide timely and takes off before the hepatic injury, has caused in the testing result the temporary vacation of model group higher.What deserves to be mentioned is that the albumin synthetic quantity of medicament group is compared higher with model group, negative control group, wherein small dose group has produced significance higher (P＜0.05).This phenomenon explanation preparation of the present invention can improve the albuminous synthesis capability of liver, may have the effect of enhancing human body immunity.
1, blood parameters: compare with model group, the small dose group decapacitation extremely significantly reduces outside the A/G (P＜0.01), can also significantly improve A/G (0.05) and significantly reduce ALT, AST (P＜0.05), but majority parameters all has significant difference (A, ALT, AST, P＜0.05) with negative control group.Heavy dose of group then can significantly reduce G (P＜0.05), ALT, AST (P＜0.01), significantly improves A/G (P＜0.01), and every index all very near with negative control group (P＞0.05).Compare with small dose group, heavy dose of group significantly reduces ALT, AST (P＜0.05) (table 6).Illustrate that this capsule has certain hepatoprotective effect to liver cirrhosis, and drug effect has dose dependent.
Table 6 preparation of the present invention to the influence of mice liver function indexes (
N=6)
The t check: compare with model group, * P＜0.05, △ P＜0.05 is compared in * * P＜0.01 with negative control, △ △ P＜0.01, big small dose group is compared, ▲ P＜0.05, ▲ ▲ P＜0.01
2. hepatic pathology: the serious edema of model group mouse liver cell, a large amount of hepatic necrosis, steatosis, cell infiltration is serious in the portal area, and tangible fibroplasia appears in regional area.Compare with model group, heavy dose of group necrocytosis, cell infiltration, the situation of fibroplasia disappear substantially, cellular edema, steatosis, the agglutinative lesion degree of endochylema is also alleviated greatly.Though small dose group has also alleviated various pathological changes to a certain extent, its effect is far away less than heavy dose group (table 7).This just illustrates that preparation of the present invention can effectively protect hepatocyte, prevents hepatocellular degeneration necrosis.And this effect has dose dependent.Liver is read sheet and standards of grading and is carried out by West China HSPH of Sichuan University Pathological Staff Room, and except that 0,1,2,3,4 fen five grade were counted in fibroplasia, all the other indexs were all counted 0,1,2,3 fen four grade.
Table 7 is respectively organized mouse liver section scoring situation
Annotate: hepatocyte edema number in three different visuals field of same section par less than 10% 1 minutes, 10-15% meter 2 minutes, 15-20% counted 3 fens; Can get the steatosis cell quantity on average less than 25% 1 minutes with method, 25-50% meter 2 minutes, 50-75% meter 3 minutes; Endochylema solidifies cell quantity on average less than 5% 1 minutes, 5-10% meter 2 minutes, 10-20% meter 3 minutes; The hepatic necrosis cell quantity is on average less than 5% 1 minutes, 5-10% meter 2 minutes, 10-20% meter 3 minutes; Fibroplasia is visible hypertrophy meter 1 minute, and obviously visible hypertrophy meter 2 minutes does not form the meter 3 minutes of whole pseudolobulis in the visual field, and whole visual field all forms the meter 4 minutes of pseudolobuli.
Two, preparation of the present invention is to the hepatalgia that viral hepatitis, alcoholic hepatitis and liver cirrhosis, hepatocarcinoma are caused and the therapeutical effect of hepatomegaly.
1. blood parameters: in month of treatment, two groups of mices have been done 4 blood samples selective examination.The result shows that after the removal cause of disease, the ALT of negative control group, the development trend of HA reduce, and are benign developments.This explanation mice has certain self-healing ability.But nonetheless, compare with the contemporaneity negative control group, medication therapy groups has still embodied the significant difference (table 8) of its healing aspect degree.And, ALT, HA after through 31 days treatment all substantially near normal value.Inductive hepatic injury has certain therapeutic effect to the preparation of the present invention that this explanation dosage is 0.25g/kg to Con A.
Table 8 preparation of the present invention to the influence of mice liver function indexes (
N=6)
The t check: matched group is compared with the treatment group, P*＜0.05, P**＜0.01
2. hepatic pathology: the om observation result shows that the hepatocyte edema of negative control group and the agglutinative symptom of endochylema worsen, and other symptom has the trend of alleviation, but wherein the alleviation situation of the symptom of steatosis and hepatic necrosis is smaller.This phenomenon explanation, mice itself is that certain self-healing ability is arranged.Compare with negative control group, all hepatic lesions indexs of medication therapy groups all have improvement in various degree, and part index number has been tending towards normally, and wherein with hepatic necrosis, liver inflammatory cell infiltration and fibroplasia is (table 9) significantly.This is explanation just, and preparation of the present invention has certain therapeutic effect to the inductive immunologic liver injury of Con A, and it can effectively remove downright bad hepatocyte, accelerates the outgrowth fibrous tissue of degraded, thereby makes the liver of pathological changes be tending towards normal.
Table 9 mouse liver section scoring situation
Above result of study shows: preparation of the present invention is to the hepatalgia that viral hepatitis, alcoholic hepatitis and liver cirrhosis, hepatocarcinoma are caused and the prevention and the therapeutical effect of hepatomegaly.
The specific embodiment
Embodiment 1
A kind of Tibetan medicinal preparation for the treatment of hepatopathy, described preparation is made of the component of following parts by weight: Mirabilitum crystallina (calcine) 83.2, Lignum Santali Albi 6.7, Lignum Dalbergiae Odoriferae 13.3, Lignum Aquilariae Resinatum 8.3, Fructus Chebulae's (enucleation) 16.7, Fructus Amomi Rotundus 3.3, Flos Carthami 8.3, Concretio Silicea Bambusae 6.7, Semen Myristicae 3.3, Fructus Tsaoko 3.3, Fructus Phyllanthi 13.3, Semen Granati 10, seed of Cortex Holarrhenae Antidysentericae 5, Fructus Piperis Longi 6.7, the Radix Aucklandiae 6.7, tangut dragonhead 13.3, Herba Swertiae bimaculatae 1.3, BAXIAGA 8.3, Herba meconopsis integrifoliae 13.3, Herpetospermum caudigerum Wall. 6.7, list loud, high-pitched sound 13.3, In vitro cultured Calculus Bovis 1.7, artificial Moschus 0.8.
Embodiment 2
A kind of Tibetan medicinal preparation for the treatment of hepatopathy, described preparation is made of the component of following parts by weight: Mirabilitum crystallina (calcine) 127, Lignum Santali Albi 10.1, Lignum Dalbergiae Odoriferae 20.3, Lignum Aquilariae Resinatum 12.7, Fructus Chebulae's (enucleation) 25.4, Fructus Amomi Rotundus 5.1, Flos Carthami 12.7, Concretio Silicea Bambusae 10.1, Semen Myristicae 5.1, Fructus Tsaoko 5.1, Fructus Phyllanthi 20.3, Semen Granati 15.2, seed of Cortex Holarrhenae Antidysentericae 7.6, Fructus Piperis Longi 10.1, the Radix Aucklandiae 10.1, tangut dragonhead 20.3, Herba Swertiae bimaculatae 2, BAXIAGA 12.7, Herba meconopsis integrifoliae 20.3, Herpetospermum caudigerum Wall. 10.1, list loud, high-pitched sound 20.3, In vitro cultured Calculus Bovis 2.5, artificial Moschus 1.3.
Embodiment 3
A kind of Tibetan medicinal preparation for the treatment of hepatopathy, described preparation is made of the component of following parts by weight: Mirabilitum crystallina (calcine) 92.5g; Lignum Santali Albi 7.4g; Lignum Dalbergiae Odoriferae 14.8g; Lignum Aquilariae Resinatum 9.3g; Fructus Chebulae's (enucleation) 18.5g; Fructus Amomi Rotundus 3.7g; Flos Carthami 9.3g; Concretio Silicea Bambusae 7.4g; Semen Myristicae 3.7g; Fructus Tsaoko 3.7g; Fructus Phyllanthi 14.8g; Semen Granati 11.1g; seed of Cortex Holarrhenae Antidysentericae 5.6g; Fructus Piperis Longi 7.4g; Radix Aucklandiae 7.4g; tangut dragonhead 14.8g; Herba Swertiae bimaculatae 1.5g; BAXIAGA 9.3g; Herba meconopsis integrifoliae 14.8g; Herpetospermum caudigerum Wall. 7.4g; list loud, high-pitched sound 14.8g; In vitro cultured Calculus Bovis 1.85g; artificial Moschus 0.93g.
Embodiment 4
A kind of Tibetan medicinal preparation for the treatment of hepatopathy, described preparation is made of the component of following parts by weight: Mirabilitum crystallina (calcine) 110g, Lignum Santali Albi 8.8g, Lignum Dalbergiae Odoriferae 17.6g, Lignum Aquilariae Resinatum 11g, Fructus Chebulae's (enucleation) 22g, Fructus Amomi Rotundus 4.4g, Flos Carthami 11g, Concretio Silicea Bambusae 8.8g, Semen Myristicae 4.4g, Fructus Tsaoko 4.4g, Fructus Phyllanthi 17.6g, Semen Granati 13.2g, seed of Cortex Holarrhenae Antidysentericae 6.6g, Fructus Piperis Longi 8.8g, Radix Aucklandiae 8.8g, tangut dragonhead 17.6g, Herba Swertiae bimaculatae 1.76g, BAXIAGA 11g, Herba meconopsis integrifoliae 17.6g, Herpetospermum caudigerum Wall. 8.8g, list loud, high-pitched sound 17.6g, In vitro cultured Calculus Bovis 2.2g, artificial Moschus 1.1g.
Embodiment 5
A kind of Tibetan medicinal preparation for the treatment of hepatopathy is characterized in that: described preparation is made of the component of following parts by weight: Mirabilitum crystallina (calcine) 106g; Lignum Santali Albi 8.5g; Lignum Dalbergiae Odoriferae 17g; Lignum Aquilariae Resinatum 10.6g; Fructus Chebulae's (enucleation) 21.2g; Fructus Amomi Rotundus 4.2g; Flos Carthami 10.6g; Concretio Silicea Bambusae 8.5g; Semen Myristicae 4.2g; Fructus Tsaoko 4.2g; Fructus Phyllanthi 17g; Semen Granati 12.7g; seed of Cortex Holarrhenae Antidysentericae 6.4g; Fructus Piperis Longi 8.5g; Radix Aucklandiae 8.5g; tangut dragonhead 17g; Herba Swertiae bimaculatae 1.7g; BAXIAGA 10.6g; Herba meconopsis integrifoliae 17g; Herpetospermum caudigerum Wall. 8.5g; list loud, high-pitched sound 17g; In vitro cultured Calculus Bovis 2.1g; artificial Moschus 1.1g.
Claims (4)
1. Tibetan medicinal preparation for the treatment of hepatopathy, it is characterized in that: described preparation is made of the component of following parts by weight: Mirabilitum crystallina (calcine) 78～127; Lignum Santali Albi 6～10; Lignum Dalbergiae Odoriferae 12～20; Lignum Aquilariae Resinatum 8～12; Fructus Chebulae's (enucleation) 15～25; Fructus Amomi Rotundus 3～5; Flos Carthami 8～12; Concretio Silicea Bambusae 6～10; Semen Myristicae 3～5; Fructus Tsaoko 3～5; Fructus Phyllanthi 12～20; Semen Granati 9～15; seed of Cortex Holarrhenae Antidysentericae 5～8; Fructus Piperis Longi 6～10; the Radix Aucklandiae 6～10; tangut dragonhead 12～20; Herba Swertiae bimaculatae 1.2～2; BAXIAGA 8～12; Herba meconopsis integrifoliae 12～20; Herpetospermum caudigerum Wall. 6～10; list loud, high-pitched sound 12～20; In vitro cultured Calculus Bovis 1.6～2.5; the artificial Moschus 0.8～1.3.
2. a kind of Tibetan medicinal preparation for the treatment of hepatopathy according to claim 1; it is characterized in that: preferred, described preparation is made of the component of following parts by weight: Mirabilitum crystallina (calcine) 100～110; Lignum Santali Albi 8～9; Lignum Dalbergiae Odoriferae 16～18; Lignum Aquilariae Resinatum 10～12; Fructus Chebulae's (enucleation) 20～22; Fructus Amomi Rotundus 4～5; Flos Carthami 10～12; Concretio Silicea Bambusae 8～9; Semen Myristicae 4～5; Fructus Tsaoko 4～5; Fructus Phyllanthi 16～18; Semen Granati 12～14; seed of Cortex Holarrhenae Antidysentericae 6～8; Fructus Piperis Longi 8～9; the Radix Aucklandiae 8～9; tangut dragonhead 16～18; Herba Swertiae bimaculatae 1.6～1.8; BAXIAGA 10～12; Herba meconopsis integrifoliae 16～18; Herpetospermum caudigerum Wall. 8～9; list loud, high-pitched sound 16～18; In vitro cultured Calculus Bovis 2～2.3; the artificial Moschus 1～1.1.
3. a kind of Tibetan medicinal preparation for the treatment of hepatopathy according to claim 1; it is characterized in that: optimum, described preparation is made of the component of following parts by weight: Mirabilitum crystallina (calcine) 106; Lignum Santali Albi 8.5; Lignum Dalbergiae Odoriferae 17; Lignum Aquilariae Resinatum 10.6; Fructus Chebulae's (enucleation) 21.2; Fructus Amomi Rotundus 4.2; Flos Carthami 10.6; Concretio Silicea Bambusae 8.5; Semen Myristicae 4.2; Fructus Tsaoko 4.2; Fructus Phyllanthi 17; Semen Granati 12.7; seed of Cortex Holarrhenae Antidysentericae 6.4; Fructus Piperis Longi 8.5; the Radix Aucklandiae 8.5; tangut dragonhead 17; Herba Swertiae bimaculatae 1.7; BAXIAGA 10.6; Herba meconopsis integrifoliae 17; Herpetospermum caudigerum Wall. 8.5; list loud, high-pitched sound 17; In vitro cultured Calculus Bovis 2.1; the artificial Moschus 1.1.
4. according to the described a kind of Tibetan medicinal preparation for the treatment of hepatopathy of any claim in the claim 1～3, it is characterized in that: described preparation is a capsule preparations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105265509A CN102058817B (en) | 2010-11-01 | 2010-11-01 | Tibetan medicinal preparation for treating liver diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105265509A CN102058817B (en) | 2010-11-01 | 2010-11-01 | Tibetan medicinal preparation for treating liver diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102058817A true CN102058817A (en) | 2011-05-18 |
| CN102058817B CN102058817B (en) | 2013-01-16 |
Family
ID=43994442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105265509A Expired - Fee Related CN102058817B (en) | 2010-11-01 | 2010-11-01 | Tibetan medicinal preparation for treating liver diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102058817B (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102441156A (en) * | 2011-12-14 | 2012-05-09 | 多吉 | Tibetan medicine composition and preparation method thereof |
| CN102580051A (en) * | 2012-03-28 | 2012-07-18 | 丁世广 | Oral liquid for treating hepatitis A |
| CN102657838A (en) * | 2012-05-31 | 2012-09-12 | 山东阿如拉药物研究开发有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating alcoholic hepatitis |
| CN103040909A (en) * | 2013-01-25 | 2013-04-17 | 西藏福田藏医药研究开发有限公司 | Tibetan medicine composition and application of composition in preparation of products for preventing and treating alcoholic liver diseases |
| CN103877475A (en) * | 2014-04-09 | 2014-06-25 | 山东大学齐鲁医院 | Oral pharmaceutical preparation for treating mania |
| CN104096108A (en) * | 2014-07-18 | 2014-10-15 | 那生桑 | Mongolian medicine for treating painful subacute thyroiditis and preparation method thereof |
| CN105250898A (en) * | 2015-10-16 | 2016-01-20 | 白玛仁增 | Compound Tibetan medicine with efficacy of detoxification and liver protection |
| WO2017011523A1 (en) * | 2015-07-15 | 2017-01-19 | Unigen, Inc. | Compositions, methods, and medical compositions for treatment of and maintaining the health of the liver |
| CN108201589A (en) * | 2016-12-19 | 2018-06-26 | 浏阳市利美免疫力修复中心有限公司 | A kind of traditional Chinese medicine composition for treating hepatitis |
| CN110123922A (en) * | 2019-06-18 | 2019-08-16 | 甘孜藏族自治州藏医院 | A kind of Tibetan medicine medicament of hemostasis |
| CN112043758A (en) * | 2020-09-25 | 2020-12-08 | 兰科加 | A Chinese medicinal composition for treating liver cirrhosis and hepatic fibrosis |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1243002A (en) * | 1999-06-21 | 2000-02-02 | 久美彭措 | Tbetan medicinal pill for treating liver disease and preparation method thereof |
| CN1283492A (en) * | 2000-08-10 | 2001-02-14 | 朋毛 | A kind of Tibetan medicine for treating liver diseases and its preparation method |
| CN1284360A (en) * | 2000-08-14 | 2001-02-21 | 久美彭措 | Tibeten medicine for treating hepatitis B and its preparation |
| CN1364488A (en) * | 2001-01-12 | 2002-08-21 | 杨孟君 | Nano thirteen ingredient Bonga aconite medicine powder and its preparing method |
-
2010
- 2010-11-01 CN CN2010105265509A patent/CN102058817B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1243002A (en) * | 1999-06-21 | 2000-02-02 | 久美彭措 | Tbetan medicinal pill for treating liver disease and preparation method thereof |
| CN1283492A (en) * | 2000-08-10 | 2001-02-14 | 朋毛 | A kind of Tibetan medicine for treating liver diseases and its preparation method |
| CN1284360A (en) * | 2000-08-14 | 2001-02-21 | 久美彭措 | Tibeten medicine for treating hepatitis B and its preparation |
| CN1364488A (en) * | 2001-01-12 | 2002-08-21 | 杨孟君 | Nano thirteen ingredient Bonga aconite medicine powder and its preparing method |
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102441156A (en) * | 2011-12-14 | 2012-05-09 | 多吉 | Tibetan medicine composition and preparation method thereof |
| CN102441156B (en) * | 2011-12-14 | 2013-06-12 | 多吉 | Traditional Tibetan medicinal composition and preparation method thereof |
| CN102580051A (en) * | 2012-03-28 | 2012-07-18 | 丁世广 | Oral liquid for treating hepatitis A |
| CN102657838A (en) * | 2012-05-31 | 2012-09-12 | 山东阿如拉药物研究开发有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating alcoholic hepatitis |
| CN102657838B (en) * | 2012-05-31 | 2013-11-06 | 山东阿如拉药物研究开发有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating alcoholic hepatitis |
| CN103040909A (en) * | 2013-01-25 | 2013-04-17 | 西藏福田藏医药研究开发有限公司 | Tibetan medicine composition and application of composition in preparation of products for preventing and treating alcoholic liver diseases |
| CN103877475A (en) * | 2014-04-09 | 2014-06-25 | 山东大学齐鲁医院 | Oral pharmaceutical preparation for treating mania |
| CN104096108B (en) * | 2014-07-18 | 2017-12-22 | 乌苏日乐特 | Mongolian medicine for treating painful methyleneitis and preparation method thereof |
| CN104096108A (en) * | 2014-07-18 | 2014-10-15 | 那生桑 | Mongolian medicine for treating painful subacute thyroiditis and preparation method thereof |
| WO2017011523A1 (en) * | 2015-07-15 | 2017-01-19 | Unigen, Inc. | Compositions, methods, and medical compositions for treatment of and maintaining the health of the liver |
| KR20180026769A (en) * | 2015-07-15 | 2018-03-13 | 유니젠, 인크. | Compositions, methods and medical compositions for the treatment of liver and liver health |
| KR102177271B1 (en) | 2015-07-15 | 2020-11-10 | 유니젠, 인크. | Composition, method and medical composition for treatment of liver and maintenance of liver health |
| RU2755475C2 (en) * | 2015-07-15 | 2021-09-16 | Юниджен, Инк. | Compositions, methods and medical compositions for treatment and maintenance of liver health |
| KR20220039839A (en) * | 2015-07-15 | 2022-03-29 | 유니젠, 인크. | Compositions, methods, and medical compositions for treatment of and maintaining the health of the liver |
| KR102470576B1 (en) | 2015-07-15 | 2022-11-23 | 유니젠, 인크. | Compositions, methods, and medical compositions for treatment of and maintaining the health of the liver |
| US11806379B2 (en) | 2015-07-15 | 2023-11-07 | Unigen, Inc. | Compositions, methods, and medical compositions for treatment of and maintaining the health of the liver |
| CN105250898A (en) * | 2015-10-16 | 2016-01-20 | 白玛仁增 | Compound Tibetan medicine with efficacy of detoxification and liver protection |
| CN108201589A (en) * | 2016-12-19 | 2018-06-26 | 浏阳市利美免疫力修复中心有限公司 | A kind of traditional Chinese medicine composition for treating hepatitis |
| CN110123922A (en) * | 2019-06-18 | 2019-08-16 | 甘孜藏族自治州藏医院 | A kind of Tibetan medicine medicament of hemostasis |
| CN112043758A (en) * | 2020-09-25 | 2020-12-08 | 兰科加 | A Chinese medicinal composition for treating liver cirrhosis and hepatic fibrosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102058817B (en) | 2013-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102058817B (en) | Tibetan medicinal preparation for treating liver diseases | |
| CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
| CN104367879A (en) | Pharmaceutical composition for chickens' internal lesion caused by overexertion and preparation method of pharmaceutical composition | |
| CN103719492A (en) | Gynostemma pentaphylla liver protecting and nourishing health-care tea and preparation method thereof | |
| CN105327205A (en) | Traditional Chinese medicine preparation for treating thyroid cancer | |
| CN103877247B (en) | Medicine being used for the treatment of decubital ulcer and preparation method thereof | |
| CN103385993B (en) | Chinese medicine preparation for treating gastric ulcer and preparation method thereof | |
| CN102068653A (en) | Medicament for preparing Tibetan medicament preparation for treating liver diseases | |
| CN109432269A (en) | A kind of Chinese medicine composition and preparation method, purposes | |
| CN103520302A (en) | Sea-buckthorn leaf anti-fatigue capsule and preparation method thereof | |
| CN104815243A (en) | Preparation method of external washing liquid for atrophic vaginitis | |
| CN106377700A (en) | Folium mori and bitter gourd tea and making method thereof | |
| CN114748603B (en) | Pharmaceutical composition for preventing and treating new coronavirus pneumonia from changing or restoring yang and application thereof | |
| CN110772564A (en) | Traditional Chinese medicine extract composition with depression mood regulating effect, preparation method thereof and traditional Chinese medicine preparation | |
| CN110368445A (en) | A kind of Chinese medicine composition and its preparation method and application for treating psoriasis | |
| CN105213807A (en) | Be used for the treatment of the medicine of type of hyperactivity of fire caused by deficiency of YIN recurrent oral ulceration | |
| CN103977367A (en) | Traditional Chinese medicament for treating qi-stagnation blood-aggregation type bedsore and preparation method thereof | |
| CN103272147B (en) | Traditional Chinese medicine preparation for curing vomiting of pregnancy | |
| CN102552743A (en) | Medicinal composition for treating diabetes and preparation method thereof | |
| CN104689151A (en) | Traditional Chinese medicine composition for treating diabetes and use of composition | |
| CN111084878A (en) | Biological medicine and medical total nutrient food for lung and respiratory system diseases and preparation method thereof | |
| CN104758733A (en) | External lotion for treating senile vaginitis | |
| CN103341094B (en) | Preparation method of powder for treating vulva squamous epithelial cell hyperplasia | |
| CN103330896B (en) | Preparation method of powder for treating postpartum nonspecific vaginitis | |
| CN102579713B (en) | Traditional Chinese medicine for treating children obesity and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130116 Termination date: 20201101 |